The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Novel insights into genomic classification and prognosis in AML
Lars Bullinger, MD, of Charité University of Medicine, Berlin, Germany, discusses novel insights into genomic classification and prognosis of acute myeloid leukemia (AML) based on a pan-European public-private partnership, The Harmony Alliance. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
